Ferring Pharmaceuticals Inc. (FPI)
Ferring Pharmaceuticals Inc. is a research-driven biopharmaceutical company devoted to commercialization of innovative products in the fields of reproductive medicine, maternal health, urology, gastroenterology, endocrinology, urologic oncology, and orthopedics.
In 2013, Ferring Pharmaceuticals Inc. purchased a 25 acre site in Parsippany, NJ. The U.S. Operations Center is a fully integrated pharmaceutical facility that houses management, administration and support, commercial operations, manufacturing, and product development. It includes a state-of-the-art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices.
Ferring International Pharmascience Center US (FIPCUS)
Ferring International Pharmascience Center US, Inc. (FIPCUS), was formed in 2008 as the drug development affiliate of Ferring Pharmaceuticals Inc. FIPCUS is responsible for U.S. Clinical R & D for both local projects (those intended for U.S. commercialization alone) as well as Global projects. As an organization, it is charged with rapid identification and development of products in the clinical specialty areas of infertility, orthopedics, gastroenterology, and urology.
Ferring Research Institute (FRI)
Ferring Research Institute Inc. (FRI) is the company’s center of excellence for peptide research. Established in San Diego in 1996, FRI now occupies a company-owned, state-of-the-art research facility in Sorrento Valley. Located in the heart of the Southern California biopharmaceutical community, the center has attracted a diverse group of highly skilled professionals representing over fifteen countries of origin.
Visit the FRI website at http://ferring-research.com.
Ferring Production Group (FPG)
In 2011, Technical Operations established Ferring Production Inc. (FPG) in the United States. In 2014 FPG announced the opening of its manufacturing site and next-generation product development laboratories in Parsippany, NJ. The new facility is designed to comply with the requirements of Good Manufacturing Practices for both the United States and the EU. The state-of-the art facility will be capable of manufacturing, vial filling, packaging, testing and warehousing of product. The controlled environment’s interior features airlocks, gowning rooms, separate air handling units, HEPA filtration, differential pressure zones, and aseptic procedures that are designed to meet the high quality standards of FDA and other regulatory agencies.
In 2013, Ferring was named as one of New Jersey’s 50 fastest growing companies by NJBiz.
Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome.
Visit the Rebiotx website at www.rebiotix.com.